First Tracks Biotherapeutics, Inc. develops antibodies that modulate key immune pathways to treat autoimmune and inflammatory diseases. The company focuses on advancing its portfolio through clinical development and execution, aiming to achieve proof of concept and global registration. It identifies, licenses, and innovates antibodies against immunological targets while facilitating global commercialization and retaining rights in key markets. First Tracks operates primarily in the biopharmaceutical sector, with a commitment to delivering solutions for patients.
